Tyligand Bioscience
Shanghai, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $30M
Overview
A clinical-stage biotech developing novel small molecule therapies for oncology and immunology through structure-based drug design.
OncologyImmunology
Technology Platform
Structure-based drug design platform utilizing X-ray crystallography and computational chemistry to develop selective small molecule therapeutics.
Opportunities
Potential to address unmet needs in oncology with novel kinase inhibitors and leverage China's growing clinical trial infrastructure for efficient development.
Risk Factors
Early-stage pipeline with unproven clinical efficacy, intense competition in kinase inhibitor space, and dependence on future financing rounds.
Competitive Landscape
Competes with numerous biotechs developing kinase inhibitors for oncology; differentiation depends on demonstrating superior selectivity or novel mechanisms compared to established players.